With drug’s FDA approval, Sagent expands oncology portfolio
SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic chemotherapy drug made by Sagent Pharmaceuticals, Sagent said Thursday.
The FDA approved topotecan hydrochloride for injection, a version of GlaxoSmithKline’s Hycamtin. The U.S. market for injectable topotecan was around $158 million in 2010, according to IMS Health.
“Topotecan is an important treatment for patients who have recurrent small-cell lung cancer sensitive disease or cervical cancer,” Sagent chairman and CEO Jeffrey Yordon said. “Our launch of topotecan reinforces Sagent’s commitment to grow our oncology portfolio, to meet the needs of oncology patients and clinicians, and to demonstrate our capabilities and expertise in injectable pharmaceuticals.”
SPNN inks deal with ViroPharma’s CinryzeSolutions support program
SARASOTA, Fla. — The Specialty Pharmacy Nursing Network has entered a partnership with ViroPharma’s CinryzeSolutions support program, a training and monitoring program for patients using ViroPharma’s Cinryze (C1 esterase inhibitor [human]) who wish to administer the drug themselves.
Cinryze is a drug administered via infusion for the treatment of hereditary angioedema, and the partnership will allow patients to receive training and follow-up support from SPNN nurses, as well as direction from their physicians.
“We are excited to deliver this high-value service offering to the CinryzeSolutions support program,” SPNN VP business development Todd Weber said. “Our goal at SPNN is to set the industry standard for delivering the highest-quality infusion nursing programs within the specialty pharmacy space.”
SXC Health Solutions to acquire MedfusionRx
LISLE, Ill. — Pharmacy benefit manager SXC Health Solutions will acquire Birmingham, Ala.-based specialty pharmacy provider MedfusionRx for $100 million, SXC said Thursday.
SXC also may pay an additional $5.5 million if unspecified performance targets are met through fiscal year 2012, the company said. MedfusionRx operates pharmacies in Alabama, Mississippi, Louisiana, Tennessee, West Virginia and Kansas, and serves more than 9,000 patients.
“Specialty pharmaceuticals are the fastest-growing area in the PBM space, and our clients recognize it as the next critical area of drug spend management,” SXC president and CEO Mark Thierer said. “This acquisition will expand our presence and enhance our capabilities in the specialty pharmacy market, which differentiates us from our peers in the mid-market PBM sector.”